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liver disease, AUROC: area under receiver operating curve. CI: confidence interval, CIT: cold 
ischaemia time, CTP: Child-Turcotte-Pugh, DBD: donation after brain death, DCD: donation 
after circulatory death, DRI: donor risk index, EGD: early graft dysfunction. ESLD: end stage 
liver disease, HBV: hepatitis B virus. HCC: hepatocellular carcinoma, HCV: hepatitis C virus. 
HR: hazard ratio, AIH: autoimmune hepatitis. HCC: hepatocellular carcinoma. INR: 
international normalised ratio. LITU: liver intensive therapy unit, LRT: liver 
retransplantation. LT: liver transplantation, MELD: model for end stage liver disease. NHS: 
National Health Services, OPTN: Organ Procurement and Transplant Network, PNF: primary 
non-function. ROC: receiver operating curve. RRT: renal replacement therapy, UK: United 
Kingdom, UKELD: United Kingdom end-stage liver disease model. UNOS: United Network of 
Organ Sharing. USA: United States of America, WHO: world health organization, WL: waiting list. 
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Abstract: 
Current diagnostic criteria for primary non-function (PNF) of liver grafts are based on 
clinical experience rather than statistical methods. A retrospective, single centre study was 
conducted of all adults (n=1,286) who underwent primary liver transplant 2000-2008 in our 
centre. Laboratory variable during the first post-liver transplant week were analysed. Forty 
two patients (3.7%) had 2-week graft failure. Transplant albumin, day-1 AST, day-1 lactate, 
day-3 bilirubin, day-3 INR and day-7 AST were independently associated with PNF on 
multivariate logistic regression. PNF score =(0.000280*D1AST)+(0.361*D1 Lactate 
)+(0.00884*D3 Bilirubin)+(0.940*D 3 INR)+(0.00153*D7 AST)-(0.0972*TxAlbumin)-
4.5503. ROC analysis showed the model AUROC of 0.912 (0.889 -0.932) was superior to the 
current United Kingdom (UK) PNF criteria of 0.669 (0.634-0.704, p<0.0001). When applied 
to a validation cohort (n=386, 34.4% patients) the model had AUROC of 0.831 (0.789 -
0.867) compared to the UK EGD criteria of 0.674 (0.624-0.721). The new model performed 
well after exclusion of patients with marginal grafts and when modified to include variables 
from the first three post-LT days only (AUROC of 0.818, 0.776-0.856, p=0.001). This model 
is superior to the current UK PNF criteria and is based on statistical methods. The model is 
also applicable to recipients of all types of grafts (marginal and non-marginal).  
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Introduction: 
Graft injury is inevitable during the process of liver transplantation (LT) to which 
ischaemia and reperfusion is an important contributor. (1) In the majority of patients, the 
manifestations of such graft injury settle rapidly within the first week following LT. 
However, in few patients measures of graft function display significant abnormalities which 
are referred to as early graft dysfunction (EGD). Patients who develop EGD have increased 
risk of graft failure or death early in the post-LT period. (2) In its most severe form, primary 
non-function (PNF), the risk of death or the requirement for emergency liver 
retransplantation (LRT) within the first 1-2 weeks are markedly increased. (3) (4) 
There is a lack of agreement on the terminology used to describe PNF. (5) The 
diagnostic criteria of PNF also varied significantly in the reported literature. (4) (6) (7) (8) (3) 
(9) (10) Initial studies suggested the use of markers of liver injury such as aspartate 
aminotransferase (AST) (3) (4) (6)  or alanine aminotransferase (ALT), (3) (6) (7) (8)  or 
markers of hepatic synthetic function such as prothrombin time,(4) (6) (7) (8) bilirubin level,  
(2) bile production,(6) (8) acidosis, (11) ammonia level (4) or hepatic encephalopathy. (2) 
The timing of measurement of these variables also varies in the literature with variables 
included on day-1 post-LT,(3) first 3 days, (8) (12) to those recorded at any day between day 
2-7 post-transplant. (4) Furthermore, the time frame of the outcome of PNF varied in the 
described studies with death or retransplantation occurring within 1 week, (6) day 2-7, (4) 
within 10 days (11) or up to 2 weeks post-LT. (3) (5) 
 In the United Kingdom (UK), the National Health Services (NHS) Blood and 
Transplant Advisory Committee set the criteria for PNF under category 9 of super-urgent 
listing for liver transplantation. (13) These criteria were based mainly on clinical experience 
utilising previously reported data (Box 1). In the United States of America (USA), the Organ 
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Procurement and Transplant Network (OPTN) described a different set of diagnostic criteria 
for PNF (Box 2). (14) In both these criteria, cut-off points were arbitrary with significant 
difference in the choice of thresholds for the 2 systems. Moreover, the UK criteria include 
bile production, based on previous practices of LT. Routine use of biliary drains to monitor 
bile output is rarely in use nowadays.  
The aims of this study were 3 fold: Firstly, to define diagnostic criteria of PNF using 
standard and transportable laboratory tests performed within the first week post-LT based on 
statistical models, secondly, to compare the diagnostic performance of the proposed criteria 
with the current UK criteria for PNF; and lastly, to internally validate the newly proposed 
criteria.   
  
6 
 
  
Box 1: NHS Blood and Transplant Liver Advisory Group diagnostic criteria for super-urgent 
listing for liver transplantation for early graft dysfunction. Box 2: OPTN urgent listing 
criteria for primary non-function.  
Box 1:       Box 2: 
 
 
 
 
 
 
 
 
 
 
Materials & Methods: 
Patients & Design: 
We performed a retrospective analysis of all adult patients (n=1,286) who had LT in 
our centre and received grafts from deceased donors between January 2000 to December 
2008. Exclusions included retransplanted patients (n=133), those who died during the 
transplant operation (n=4), had hepatic artery thrombosis (n=19) as a cause of graft failure 
and 5 patients who had early death secondary to metastatic cancers. Therefore, data was 
analysed on 1125 patients.  
 
 
 
Early graft dysfunction on days 0 to 
7 after liver transplantation with at 
least two of the following:  
1. AST >10,000 IU/l 
2.  INR >3.0 
3. Serum lactate >3 mmol/l 
4.  Absence of bile production. 
 
Primary non-function of a 
transplanted liver within 7 days of 
implantation; as defined by (a) or 
(b):  
(a) AST ≥ 3,000 and one or both of 
the following:  
 INR ≥ 2.5  
 Acidosis, defined as having 
an arterial pH ≤ 7.30 or 
venous pH of 7.25 and/or 
Lactate ≥ 4 mmol/l  
(b) Anhepatic candidate 
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Dataset: 
All patients who had LT in our centre were admitted from operating theatre to liver 
intensive therapy unit (LITU). All patients admitted to LITU had daily clinical, physiological, 
laboratory variables and requirement for organ support prospectively recorded into LITU 
database. This dataset, electronic patient record and the clinical notes were utilised to 
summate demographic, clinical, and laboratory data at the time of listing, at time of transplant 
and for the first week following LT. Variables determined daily included AST, bilirubin, 
INR, lactate, creatinine, requirement for vasopressors and renal replacement therapy (RRT). 
Prognostic models were calculated at the time of listing and at transplant. Model for 
end stage liver disease (MELD) score was calculated according to the United Network of 
Organ Sharing (UNOS) adjustments. (15) The UK end stage liver disease (UKELD) score 
was calculated according to Barber et al. (16) Donor and graft variables assessed were age, 
gender, donor-to-recipient gender mismatch, ethnicity, donor-to-recipient blood group 
mismatch, height, weight, body mass index (BMI), graft type: donation after brain death 
(DBD) versus donation after circulatory death (DCD), organ type (whole versus non-whole) 
and cold ischemia time (CIT). The donor risk index (DRI) was calculated according to Feng 
et al. (17)  Marginal grafts were defined as grafts with DRI > 1.8. (18) Grafts were also 
categorised as marginal and non-marginal according to surgical inspection of the grafts by the 
unit’s transplant surgeons. 
Definitions of outcome measures: 
Patient survival was documented according to their recorded survival status in our 
hospital information system. According to previously published reports, we chose death or 
the requirement for LRT within 2 weeks of primary liver transplant (PLT) as the primary 
outcome to define PNF (3) (5) (19) . 
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Ethical approval: 
Ethical approval for interrogation, analysis and publication of this anonymised dataset 
was obtained from the Southeast London Research Ethics Committee 3 (previously known as 
King’s College Hospital Research Ethics Committee). 
Statistical Analysis: 
Data were assessed for normality using the D’Agostino Pearson test. Comparisons 
were made by Student’s t-test (one way ANOVA) or Mann Whitney (Kruskall-Wallis) for 2 
(or more) comparison groups. Categorical data were compared using the Chi square (χ2) test. 
Univariate and multivariate (backwards mode) logistic regression and area under the receiver 
operating curves (AUROC) analysis were performed for 2-week outcomes.  To assess 
goodness of fit, the Hosmer and Lemeshow test was calculated where a p-value of <0.05 was 
used to reject variables or models for failing to adequately pass the comparison of observed 
and expected outcomes due to over-fitting. In multivariate regression, backwards mode, the 
criterion for exclusion was a p-value of 0.15 to balance the need for a parsimonious model 
while reducing potential bias from suppressor effects. Therefore, a three-stage filtering 
process was used where a variable was removed if a) it was radically alterable by therapy, b) 
if it failed the Hosmer and Lemeshow test (p<0.05) and c) if the p value was >0.15 on 
backward regression. Data were assessed for multiple collinearity using correlation 
coefficients. For an R>0.4 the predictor with the highest regression coefficient was retained. 
In order to minimise reductions in specificity while attempting to improve sensitivity, 
specificity was fixed a priori at 95% in deciding cut-offs for any logistic regression models. A 
second repeated measures logistic regression model was fitted where all data were added to 
the model to assess for any bias in the above variable selection method as described in the 
supplementary material.   Significance was required at the 95% level with a 2 tailed p-value 
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of <0.05. Data were analysed in Excel (Microsoft), SPSS 17 (IBM) and MedCalc v 12.2.0 
(Mariakerke, Belgium). 
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RESULTS 
Recipient, donor and graft descriptive results: 
Forty-two patients (3.7%) had graft failure within 2 weeks of PLT. Twenty-four 
patients (2.1%) died and 18 patients (1.6%) had LRT within 2 weeks of PLT. Recipient 
characteristics are summarised in table 1. There were no significant differences in 
demographic variables or aetiology of liver disease between patients who had 2-week graft 
failure compared to those who did not, except for a higher proportion of patients transplanted 
with acute liver failure (ALF) in the 2-week graft failure group. At transplant, patients with 
graft failure had lower albumin level, higher bilirubin, creatinine, INR, sodium (Na) levels 
and MELD score. Donor and graft variables were not significantly different between the 2 
groups except for higher proportion of ABO mismatch, gender mismatch and higher donor 
body mass index (table 1). Grafts assessed as non-optimal had a higher DRI than those 
assessed as optimal 1.68 (1.00-3.70) vs 1.61 (0.93-3.90), p=0.02. Non-optimal livers had 
higher day-1 AST 663 (39-13886) vs 568 (27-11140), p=0.001. However, no relationship 
between PNF and graft weight, graft assessment or blood group was observed. On univariate 
analysis these variables did not reach significance and therefore were not included in 
subsequent multivariable analysis. DRI, proportion of patients with marginal grafts, DCD 
grafts, partial grafts and CIT were not significantly different between the two groups. 
By expanding the definition of PNF to 2 weeks in total 42 cases were identified 
compared to 27 who met the USA definition in this time frame and only 14 who met the UK 
definition in this time frame.  
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Post-transplant biochemical data: 
Lactate, AST, bilirubin, INR and creatinine showed a general trend of decline within 
the first post-transplant week except for bilirubin and creatinine levels for patients with 2-
week graft failure (figure 1). Lactate, AST, bilirubin, INR and creatinine were significantly 
higher in patients who had 2-week graft failure compared to those whom the graft survived 
for more than 2 weeks (table 2).  
Derivation and validation cohorts 
A randomly generated index was used to split the data into derivation and validation 
cohort (65% and 35% of the entire cohort, respectively). Data were matched (p>0.05) 
between the derivation and validation sets for >95% of variables (see Supplementary table). 
Factors associated with PNF: 
Univariate and multivariate logistic regression analysis are shown in Table 3. There 
were a large number of variables which on univariate analysis could be initially justified in 
progressing to multivariate analysis based on p-value alone. Of note, DRI and DCD status did 
not have univariate significance for predicting this short-term outcome. We employed two 
methods to help simplify the regression model. First, if a variable was prone to bias in terms 
of being potentially modifiable by treatment (eg. serum creatinine or decision to 
continue/start RRT) and second, statistically, if the Hosmer and Lemshow p-value was <0.05 
there was a danger of poor fit in any subsequent model. Using these filters, we identified 
transplant albumin, day-1 AST, day-1 lactate, day-3 bilirubin, day-3 INR and day-7 AST as 
independent factors associated with PNF. Day-1 and day-7 AST were not closely correlated 
(r=0.05, p=0.010). MELD score at transplantation as a continuous or categorical variable 
with cut off value of 25 (20) (21)or 30 (22) was not associated with PNF on multivariate 
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analysis. Based on these findings, we constructed a model composed of the aforementioned 
variables in the first week post-LT. This PNF score =(0.000280*D1AST)+(0.361*D1 Lactate 
)+(0.00884*D3 Bilirubin)+(0.940*D 3 INR)+(0.00153*D7 AST)-(0.0972*TxAlbumin)-4.5503. 
Diagnostic performance of the PNF model compared to existing models: 
We compared our model with the UK category 9 criteria for super urgent listing (box 
1) and with the USA OPTN diagnostic criteria for PNF (box 2). Figure 2 illustrates ROC 
analysis that demonstrates superior performance of the new PNF diagnostic model with 
AUROC of 0.912 (0.889 -0.932) compared to the UK EGD criteria of 0.669 (0.634-0.704, 
p<0.0001 for pairwise comparison to the new model) and the USA PNF criteria of 0.776 
(0.774-0.806, p=0.010 for pairwise comparison to the new model). Our model also showed 
significant improvement in the sensitivity of the model in detecting patients with PNF (73%) 
compared to the UK (31%) and USA (66%) criteria (table 4).  
Validation of the new model: 
The same model was applied to the validation cohort of 386 (34.4%) randomly 
selected patients. The proposed model had AUROC of 0.831 (0.789 -0.867) compared to the 
UK EGD criteria of 0.674 (0.624-0.721) and the USA PNF criteria of 0.781 (0.736-0.822) as 
shown in figure 2.  
Earlier detection of PNF: 
 Giving the importance of earlier detection and diagnosis of PNF to be able to offer 
patients with PNF a curative treatment (retransplantation), we modified the above model to 
include variables from the first 3 days post-transplant only. This PNF score =(0.000280*D1 
AST)+(0.361*D1 Lactate )+(0.00884*D3 Bilirubin)+(0.940*D3 INR)-(0.0972*TxAlbumin)-
4.5503. This model also performed well with AUROC of 0.818 (0.776-0.856, p=0.001). 
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Pairwise comparison of AUROC of the two models (including and excluding day-7 variables) 
showed small and non-significant change of 0.83 v 0.82, p=0.321, figure 4).  
Application of the model to recipients of marginal grafts: 
Published reports on this topic varied with regards to the inclusion or exclusion of 
groups of patients such as patients with ALF, recipients of DCD grafts and recipients of 
partial or split grafts. We compared the diagnostic performance of our model on the entire 
validation cohort and after exclusion of each of the sub groups mentioned above as illustrated 
in figure 3. The new model continued to perform well after exclusion of recipients of DCD 
grafts and recipients of partial grafts but there was a drop in the AUROC from 0.840 to 0.795 
after exclusion of patients transplanted for ALF. Despite the decrease in AUROC, our model 
continued to discriminate well between those who met the outcome definition of PNF from 
those who did not (p=0.041). 
Effect of renal support  
 
When modelled with the dichotomous variable of whether the patient received haemo-
filtration on that day, only CVVHF on day 7 was independently associated with PNF and 
therefore added into the model. The modified model had an AUROC of 0.828 so there was no 
benefit in its addition.  
 
Addition of serum creatinine from all measured post-transplant days did not improve the 
model and none of the creatinine measurements were statistically significant in terms of 
prognostic performance when forced into logistic regression models  
 
Assessment of proposed model versus repeated measures logistic regression 
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We also performed a repeated measures logistic regression model, initially with all IV 
entered. The final model included AST, lactate, bilirubin and requirement for vasopressor 
therapy with highly significant predictive accuracy and a sensitivity of 71 (55-84)% and 
specificity of 95 (92-97)%. This was essentially the same as with the original proposed 
model.  
  
 
 
DISCUSSION: 
 The diagnostic criteria for primary non-function in the UK are described under 
category-9 of super-urgent listing for retransplantation under the title of early graft 
dysfunction. (13) These criteria were based on clinical experience and liver transplant 
practices of approximately 2 decades ago.  During the last 20 years, significant progress was 
achieved in the field of liver transplantation such as improvements in operative methods, 
immunosuppression and post-operative ICU care. (23) This resulted in the current 1- and 5-
year survival rates post-transplant of 90% and > 50%, respectively. Despite this 
improvement, 2.7-6.9% can develop primary non-function with high early post-transplant 
mortality without retransplantation. (3) (4) (7)  
 This is the largest study to date to investigate the diagnostic criteria of primary liver 
graft non-function. This study has a number of design strengths compared to previous reports 
which are worth exploring. (3) (4) (7) (8) First, we set our diagnostic method based on 
composite of outcome variables of death and retransplantation rather than categorising graft 
function according to laboratory variables. Second, we chose the time interval of the 
composite outcome measure of 2-week post-transplant to include patients who met the 
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current UK diagnostic criteria by the end of the first week who would have been 
retransplanted or died within the second week. This was also in agreement with Strasberg et 
al. suggestion on extending the time interval for the diagnosis of PNF from 1-week to 2-week 
outcome in an attempt to refine the definition of PNF; and in agreement with other authors. 
(3) (5) (19) Third, this study focused on adult patients to avoid any heterogeneity in the 
patient population whilst previous studies included adults and paediatric patients. Fourth, we 
excluded patients who developed graft dysfunction or died because of HAT, those who died 
during the transplant procedure and patients who developed graft dysfunction or died 
following a second or subsequent transplant which homogenise the patient population.  
 The rate of PNF according to this paper definition was 3.7% which is significantly 
lower than 5.8% reported by Johnson and colleagues utilising SRTR database of > 10,000 
patients and lower than 6-9.2% reported by single centre series. (19) (24) (25) We identified a 
large number of variables which were associated with graft failure on univariable analysis in 
addition to those documented in table 4 such as requirement for RRT, creatinine level, 
requirement for vasopressors and mechanical ventilation during the first week post transplant. 
However, we excluded modifiable variables such as the requirements for RRT, creatinine 
level or vasopressor support and other variables which might simply reflect a severity of 
illness such as requirement for mechanical ventilation in critically ill patients . Other 
variables were excluded according to statistical methods (goodness of fit). 
 There is evidence that the severity of recipient illness may have an impact on early 
post-transplant outcomes. High MELD score at transplantation (cut off values 25 or30 ) was 
associated with reduced 3- and 12-month post-transplant survival. (20) (21) (22) (26) Our 
analysis showed that neither MELD (as continuous or categorical variable) nor its 
components were associated with PNF after controlling for other pre- and post-transplant 
variables. This finding was consistent with Johnson et al. who used the same definition of 
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PNF in an analysis of SRTR database of 10,545 patients and showed no association of MELD 
with PNF. Furthermore, the rate of PNF after the implementation MELD score for listing in 
USA was relatively stable at approximately 6% which indicates that despite transplanting 
sicker patients, the rate of PNF did not change. (19)  
 However, our model included serum albumin at transplantation as a surrogate marker 
of recipient severity of illness. Serum albumin is one of the five components of the well 
established Child-Turcotte-Pugh model, a system used over four decades to assess severity of 
illness in patients with chronic liver disease. (27) More recently, serum albumin was found to 
have inverse linear relationship to waiting list mortality analysing UNOS database and in a 
single Canadian transplant cohort. Albumin was independent of MELD in predicting waiting 
list mortality. Moreover, the addition of serum albumin to MELD and MELDNa (5 variable 
MELD) significantly improved its ability to identify patients at risk of death on the transplant 
waiting list. (28) (29) (30).  
We constructed our model for the diagnosis of PNF based on easily obtainable 
laboratory parameters during the first post-transplant week. Our multivariable regression 
model identified albumin level at transplant, day-1 blood lactate and AST levels, day-3 
bilirubin and INR levels, and day-7 AST as factors independently associated with PNF. 
Blood lactate is already in use as part of the diagnostic criteria for PNF in the UK and USA. 
(13) (14)  Blood lactate is a bi-product of anaerobic metabolism secondary to abnormal tissue 
microcirculatory perfusion and oxygenation. (31) It is mainly metabolised by the liver and 
therefore, higher blood lactate levels may reflect both increased production and impaired 
clearance in patients with hepatic dysfunction. (32) Unsurprisingly, AST and INR were 
included in our model based on statistical methods. High AST levels post-transplant indicates 
acute graft injury and INR reflects the graft synthetic function and are both included in the 
current UK and USA criteria for PNF. (13) (14) We identified bilirubin level as an 
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independent factor associated with PNF. Although bilirubin is not included in the current UK 
or USA criteria for PNF, bilirubin was associated with graft dysfunction in previous reports. 
(2) (9) (33)  
It is believed that earlier liver retransplantation of patients with graft failure within the 
first post-transplant week carries higher survival compared to retransplantation between the 
second to fourth weeks. (34) (24) Giving the importance of early diagnosis of PNF, we 
modified our model to include variables from the first 3 post-LT days. The modified model 
showed good diagnostic performance with AUROC of 0.82 which was not significantly 
different to AUROC of 0.83 for the original model which utilises day-7 variables. This 
indicates that the modified model can detect patients with PNF as early as the third post-
operative day. Should these criteria become utilised for super-urgent listing, it can facilitate 
earlier listing of patients with PNF for LRT. 
The diagnostic performance of our model was excellent when applied to the 
derivation cohort with AUROC 0.912. Although there was a reduction in the diagnostic 
performance of the model when applied to the validation cohort with AUROC of 0.83, the 
model had very good diagnostic performance compared to exiting UK and USA diagnostic 
criteria. (35) We demonstrated a significant improvement in the sensitivity of this model 
(73%) compared to the existing UK (31%) and USA diagnostic criteria for PNF (66%). This 
was achieved without significant reduction in specificity of 95% compared to specificity of 
93% and 98% for both USA and UK criteria, respectively. This model also has significantly 
improved negative likelihood ratio (LK-) of 0.3 compared to existing models of 0.7 and 0.6 
for UK and USA PNF models, respectively indicating superior discrimination of our model in 
ruling out cases who did not meet the outcome definition of 2-week graft failure, assuming 
the model is subsequently validated. (36) 
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Initial poor function of the graft may be attributed to donor or graft variables. (3, 4, 
37) Therefore, we applied our model to the validation cohort before and after exclusion of 
recipients of DCD organs and patients who received partial grafts. The performance of the 
new model assessed by ROC characteristics did not alter significantly with AUROC of 0.840, 
0.854 and 0.821, respectively. This indicates that this model can be applied to recipients of all 
graft types (marginal and non-marginal) without significant difference in its diagnostic 
performance. Furthermore, none of the donor or graft variables including the use of marginal 
grafts with DRI > 1.8 was associated with PNF on logistic regression. The reported literature 
varied with regards to the impact of graft and donor quality on the development of PNF. 
Makowka et al. found no impact of donor variables on the development of PNF. (7) Others 
found split or reduced grafts, advanced fatty changes in the graft, longer cold or warm 
ischaemia times, older donor age, donor renal insufficiency, ICU length of stay > 3 days, 
donor weight > 100kg, duration of the anhepatic phase and DCD grafts were associated with 
poor graft function. (3) (4) (19, 37) (38) (39) Findings of these reports are difficult to 
compare to ours for a number of reason. Firstly, different local practices of donor recipient 
matching, secondly, different definitions of PNF (as diagnostic criteria or time frame) and 
lastly different era of transplant practices in some of these studies.  
There are several limitations to this study. Firstly, it represents a single centre 
experience and therefore, applicability of the results to other patient populations may be 
limited. Secondly, operative data such as operation time, volume of blood loss, intra-
operative transfusion requirements, preservation solutions used and warm ischaemia time 
were not available to us and accordingly were not included in our analysis. These variables 
could be associated with early post-transplant outcomes. (3) (4) (8) (40) Finally, data on 
immunosuppression were not included in this study; however, all patients received standard 
immunosuppression according to our institution guidelines.  
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It is interesting that using a more formal approach to repeated measures without significant 
supervised variable selection led to a model with similar prognostic accuracy. The model we 
propose is a relatively simple equation and unless these more data driven techniques can 
provide much higher accuracy we do not recommend them at present. Also, they require data 
to day 7 and our model can allow stratification at day 3 where prompt preparations for re-
transplantation can be started. 
While we performed several steps to statistically validate the findings of our analysis and 
model this should not be taken as a final external validation. Particularly since we define PNF 
in a novel manner then an assessment of improved accuracy and/or survival at several centres 
would need to be made before changes in practice can be recommended. We make a 
distinction between PNF and end stage graft dysfunction beyond 2 weeks’ post-transplant 
which is likely to present as a different clinical entity (putatively called early graft 
dysfunction). For our PNF model rapid assessment and decisions regarding re-transplant can 
be biased by clinical decisions made outside the modelled parameters and therefore we invite 
and recommend more robust external validation of the increased sensitivity suggested by our 
model.  
 
Given that there are differing definitions of PNF between Europe, North American and Asia 
it would be particularly useful to validate the findings of this score in other centres firstly in 
the UK and then internationally to assess any bias both from our approach and those where 
relisting decisions for PNF use alternative criteria.  
 
In conclusion, this study addresses a life-threatening complication of liver transplantation 
(PNF) and revisits the diagnostic criteria of this complication in the MELD and UKELD era 
based on acceptable outcome definition. Our proposed criteria utilise easily obtainable and 
20 
 
objective laboratory parameters and it is based on statistical methods. Further, we have 
shown that our criteria can be modified to obtain earlier diagnosis of PNF with preservation 
of its diagnostic performance. Our diagnostic criteria are also applicable to recipients of all 
types of grafts (marginal and non-marginal). We invite the transplant community in the UK 
to externally validate our model to improve the current diagnostic criteria for PNF. 
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Table 1: Recipient, graft and donor characteristics for all patients and comparison of 
variables between patients who met the definition of 2-week graft failure and those who did 
not.  
Recipient parameters 
All patients 
n=1125 
2-week graft failure 
p-value No, n=1083 Yes, n=42 
Demographic 
   Age (years) 51 (16-74) 51(16-74) 48(18-68) 0.196 
   Gender: male (%) 679 (60.4) 657 (60.7) 22 (52.4) 0.282 
Hepatocellular carcinoma (%) 177 (15.7) 173 (16.0) 4 (9.5) 0.260 
Aetiology 
   Viral (%) 286 (25.4) 276 (25.5) 10 (23.8) 0.807 
   ALD (%) 225 (20.0) 217 (20.0) 8 (19.0) 0.875 
   AIH / Cholestatic (%) 215 (19.1) 212 (19.6) 3 (7.1) 0.045 
   Acute liver failure 177 (15.7) 161 (14.9) 16 (38.1) <0.001 
   Cryptogenic (%) 71 (6.3) 69 (6.4) 2 (4.8) 1.000 
   Other (%) 151 (13.4) 148 (13.7) 3 (7.1) 0.353 
Transplant laboratory variables  
  Albumin (g/dl) 2.9 (0.7-5.6) 2,9 (0.7-5.6) 2.4 (0.9-4.4) <0.001 
   Bilirubin mg/dl 3.0 (0.1-53.9) 3.0 (0.1-53.9) 3.7 (0.5-31.1) 0.044 
   Creatinine µmol/l 1.1 (0.4-11.5) 1.1 (0.4-11.5) 1.2 (0.8-4.8) 0.004 
   INR 1.34 (0.83-16.00) 1.3 (0.8-16.0) 1.7 (1.0-15.0) 0.002 
  Sodium (meq/l) 137 (112-159) 137 (112-159) 139 (126-150) 0.014 
   MELD 16 (6-40) 16 (6-40) 21 (7-40) 0.002 
   UKELD 55 (41-80) 55(41-77) 56(49-80) 0.060 
Donor & graft variables 
   Age (years) 47 (11-82) 47 (11-82) 45 (16-76) 0.532 
   Gender: male (%) 564 (50.1) 542 (52.0) 22 (53.7) 0.831 
   Ethnicity: European (%) 1022 (96.1) 984 (96.2) 38 (92.7) 0.217 
   Gender mismatch (%) 456 (42.1) 432 (41.4) 24 (58.5) 0.029 
   ABO blood group mismatch (%) 94 (8.5) 84 (7.9) 10 (23.8) <0.001 
   Donor height (cm) 170 (130-198) 170 (130-198) 170 (148-193) 0.645 
   Donor weight (kg) 75 (30-140) 75 (30-140) 75 (54-117) 0.076 
   BMI (kg/m2)  25 (12-47) 25 (12-47) 26 (18-35) 0.030 
   Graft weight (g) 1455 (230-2815) 1480 (916-2220) 1461 (230-2815)  
   Donor cause of death: CVA (%) 738 (65.6) 711 (66.9) 27 (64.3) 0.726 
   Graft type: split or reduced (%) 143 (12.9) 136 (12.8) 7 (16.7) 0.460 
   Donation after cardiac death (%) 91 (8.2) 87 (8.2) 4 (9.5) 0.772 
   Cold ischaemia time (hours) 10.1 (0.9-20.5) 10.1 (0.9-20.5) 10.6 (5.2-19.1) 0.334 
   DRI 1.7 (0.9-3.7) 1.7 (0.9-3.7) 1.7 (1.1-2.7) 0.568 
   Non-optimal grafts 458 (41.6) 441 (41.6) 17 (41.5) 0.889 
   Marginal grafts-DRI > 1.8 (%)  297 (26.4) 286 (26.4) 11 (26.2) 0.972 
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Table 2: Comparison of post-transplant biochemical profile according to 2-week graft 
failure. 
Variable 
2-week graft failure 
p-value No, n=1083 Yes, n=42 
D1 AST (IU/l) 612 (27-13,886) 1650 (34-12,200) <0.001 
D1 Bilirubin (mg/dl) 2.9 (0.1-38.5) 4.3 (0.5-33.2) 0.010 
D1 Creatinine (mg/dl) 1.2 (0.1-6.3) 1.5 (0.8-3.7) <0.001 
D1 INR 1.4 (0.9-7.6) 1.7 (1.0-9.8) <0.001 
D1 Lactate 1.3 (0.3-11.2) 3.2 (0.9-17.0) <0.001 
D2 AST (IU/l) 301 (21-8288) 1209 (47-8078) <0.001 
D2 Bilirubin (mg/dl) 2.3 (0.1-32,3) 5.1 (0.6-33.2) <0.001 
D2 Creatinine (mg/dl) 1.3 (0.4-6.8) 1.7 (0.8-3.2) 0.002 
D2 INR 1.2 (0.5-5.1) 1.4 (0.9-6.9) <0.001 
D2 Lactate (mmol/l) 1.2 (0.3-10) 2.0 (0.6-20) <0.001 
D3 AST (IU/l) 154 (1-4223) 774 (49-5365) <0.001 
D3 Bilirubin (mg/dl) 2.7 (0.1-22.4) 5.4 (0.4-25.1) <0.001 
D3 Creatinine (mg/dl) 1.2 (0.4-20.9) 1.6 (0.7-4.1) <0.001 
D3 INR 1.1 (0.8-4.1) 1.4 (0.9-4.4) <0.001 
D3 Lactate (mmol/l) 1.1 (0.4-10.0) 2.0 (0.7-10.5) <0.001 
D4 AST (IU/l) 92 (12-3408) 395 (20-2328) <0.001 
D4 Bilirubin (mg/dl) 3.3 (0.1-37.2) 6.6 (0.6-21.7) <0.001 
D4 Creatinine (mg/dl) 1.1 (0.2-8.0) 1.7 (0.2-3.4) <0.001 
D4 INR 1.1 (0.8-4.4) 1.2 (0.9-7.0) <0.001 
D4 Lactate (mmol/l) 1.2 (0.3-11.2) 1.9 (0.8-12.7) <0.001 
D7 AST (IU/l) 62 (9-3662) 158 (22-10040) <0.001 
D7 Bilirubin (mg/dl) 2.9 (3-760) 6.3 (0.8-21.9) <0.001 
D7 Creatinine (mg/dl) 1.1 (0.5-7.4) 1.6 (0.7-3.4) <0.001 
D7 INR 1.0 (0.8-3.1) 1.1 (0.9-3.9) <0.001 
D7 Lactate (mmol/l) 1.4 (0.4-8.8) 2.2 (0.8-24.9) <0.001 
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Table 3: Factors associated with 2-week graft failure on univariate and multivariate logistic 
regression statistics in the randomly selected derivation cohort (n=739, 65.7%). 
  Univariate Multivariate 
 Variables OR  95% CI P-value OR  95% CI P-value 
Demographic 
  Age 0.973 0.948-0.999 0.039       
  Gender  1.207 0.568-2.567 0.625       
Aetiology 
  ALD 1.043 0.417-2.611 0.928       
  Viral 0.937 0.394-2.230 0.883       
  AIH/Cholestatic 0.307 0.072-1.307 0.110       
  ALF 3.728 1.710-8.127 0.001       
  HCC 0.364 0.085-1.552 0.172       
At transplant 
  Albumin (g/dl) 0.914 0.870-0.960 <0.001 0.9073 0.8429-0.9766 0.001 
  Bilirubin (mg/dl) 1.002 1.000-1.004 0.030       
  Creatinine (mg/dl) 1.002 0.999-1.005 0.113       
  INR 1.15 1.033-1.279 0.011       
  Na 1.058 0.997-1.123 0.065       
  MELD 1.058 1.022-1.095 0.001       
  MELD >25 2.369 1.108-5.062 0.026    
  MELD >30 3.892 1.808-8.378 0.001    
  UKELD 1.052 0.998-1.109 0.061       
Graft and donor  
  Age 0.989 0.965-1.013 0.36       
  ABO mismatch 4.855 2.049-11.505 <0.001       
  Donor weight (kg) 1.033 1.007-1.061 0.014       
  BMI (kg/m2) 1.099 1.020-1.185 0.013       
   Graft weight 1.005 0.999-1.001 0.332    
  CIT 1.083 0.957-1.226 0.208       
  Split or reduced grafts (%) 1.012 0.345-2.971 0.983       
  DCD grafts 1.308 0.384-4.453 0.668       
   Optimal vs non-optimal 0.992 0.572-1.869 1.00    
  DRI  1.006 0.369-2.743 0.991       
  DRI >1.8 1.001 0.436-2.297 0.998       
Post transplant 
  D1 AST (IU/l) 1.001 1.000-1.001 <0.001 1.0003 1.0000-1.0005 0.039 
  D1 Bilirubin (mg/dl) 1.006 1.002-1.009 <0.001       
  D1 Creatinine (mg/dl) 1.005 1.001-1.010 0.012       
  D1 INR 2.338 1.639-3.335 <0.001       
  D1 Lactate (mmol/l) 1.627 1.397-1.896 <0.001 1.4351 1.1813-1.7435 <0.001 
  D1 Na (meq/l) 1.093 1.008-1.186 0.032       
  D2 AST (IU/l) 1.001 1.000-1.001 <0.001       
  D2 Bilirubin (mg/dl) 1.008 1.004-1.011 <0.001       
24 
 
  D2 Creatinine (mg/dl) 1.003 0.999-1.008 0.117       
  D2 INR 2.548 1.622-4.002 <0.001       
  D2 Lactate (mmol/l) 1.881 1.442-2.454 <0.001       
  D2 Na (meq/l) 1.075 1.002-1.153 0.044       
  D3 AST (IU/l) 1.001 1.001-1.002 <0.001       
  D3 Bilirubin (mg/dl) 1.01 1.005-1.014 <0.001 1.0089 1.0031-1.0147 0.003 
  D3 Creatinine (mg/dl) 1.001 0.999-1.004 0.290       
  D3 INR 4.807 2.514-9.189 <0.001 2.5611 1.1855-5.5327 0.017 
  D3 Lactate (mmol/l) 1.578 1.287-1.936 <0.001       
  D3 Na (meq/l) 1.118 1.047-1.193 0.001       
  D4 AST (IU/l) 1.003 1.002-1.004 <0.001       
  D4 Bilirubin (mg/dl) 1.006 1.002-1.010 0.002       
  D4 Creatinine (mg/dl) 1.003 1.000-1.007 0.061       
  D4 INR 22.179 6.455-76.206 <0.001       
  D4 Lactate (mmol/l) 1.781 1.295-2.450 <0.001       
  D4 Na (meq/l) 1.156 1.081-1.236 <0.001       
  D7 AST (IU/l) 1.002 1.001-1.003 0.005 1.0015 1.0005-1.0025 0.003 
  D7 Bilirubin (mg/dl) 1.004 1.000-1.007 0.029       
  D7 Creatinine (mg/dl) 1.005 1.001-1.008 0.008       
  D7 INR 16.353 5.294-50.517 <0.001       
  D7 Lactate (mmol/l) 1.475 1.119-1.944 0.006       
  D7 Na (meq/l) 1.107 1.027-1.193 0.008       
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Table 4: Comparison of the performance of the proposed model to the current UK and USA 
models. 
 
Factor 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
LR+  
(95% CI) 
LR-  
(95% CI) Accuracy 
Proposed model 73 (39-94)% 95 (92-97)% 13.4 (7.6-23.3) 0.3 (0.1-0.8) 0.909 
UK Category 9 criteria (PNF) 31 (9-61)% 98 (97-99)% 19 (6-60) 0.7 (0.5-1) 0.971 
USA OPTN PNF criteria 66 (46-82)% 93 (92-95)% 10.6 (7.2-15.6) 0.4 (0.2-0.6) 0.926 
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Supplementary table: Comparison of derivation and validation cohorts.  
Variables Derivation Validation P-value 
Total = 1109 727 382   
Liver related death or LRT within 2 weeks (Y:N) 23:704 10:372 0.747 
Demographic 
  Age 51(16-72) 51(17-74) 0.990 
  Gender (male:female) 457:270 213:169 0.025 
Aetiology 
  Viral (Y/N)) 183:544 99:283 0.583 
  ALF (Y:N) 105:622 65:317 0.297 
At listing 
  Albumin (g/dl) 3,0(0.9-5.0) 3.0(0.9-7.9) 0.868 
  Bilirubin (mg/dl) 2.6(0.1-43.4) 2.6(40.2-49.7) 0.930 
  Creatinine (mg/dl) 1.0(0.4-10.1) 1.0(0.5-9.3) 0.622 
  INR 1.22(0.85-5.82) 1.24(0.77-76.0) 0.348 
  Na (meq/l) 136(117-149) 137(121-147) 0.504 
  MELD 14(3-43) 14(2-35) 0.820 
  UKELD 54(38-75) 55(41-71) 0.897 
At transplant 
  Albumin (g/dl) 2.9(0.9-5.0) 2.9(0.7-7.1) 0.551 
  Bilirubin (mg/dl) 2.6(0.1-42.5) 2.6(0.2-49.7) 0.930 
  Creatinine (mg/dl) 1.1(0.4-11.5) 1.1(0.4-7.8) 0.953 
  INR 1.31(0.83-16.0) 1.36(0.85-15.0) 0.172 
  Na (meq/l) 137(112-159) 138(120-157) 0.144 
  MELD 16(6-59) 17(6-58) 0.251 
  UKELD 55(41-77) 55(42-73) 0.950 
Graft and donor  
  Age 47(11-82) 46(11-79) 0.417 
  BMI (kg/m2) 24.9(12.3-47.3) 24.7(14.9-47.3) 0.940 
  CIT (minutes) 604(55-1231) 598(237-1202) 0.800 
  Split or reduced grafts (Y:N) 99:621 42:330 0.292 
  DCD grafts (Y:N) 60:660 31:341 0.908 
  DRI  1.7(0.9-3.7) 1.6(1.0-3.4) 0.071 
  AST(iU/L) 36(1-786) 38(8-815) 0.122 
Post transplant 
  D1 AST (IU/l) 625(28-11204) 616(27-13886) 0.916 
  D1 Bilirubin (mg/dl) 3.0(0.1-38.4) 2.7(0.1-23.8) 0.243 
  D1 Creatinine (mg/dl) 1.2(0.2-5.8) 1.2(0.1-6.3) 0.337 
  D1 INR 1.43(0.93-7.60) 1.41(0.92-9.82) 0.727 
  D1 Lactate (mmol/l) 1.3(0.1-17.0) 1.3(0.1-14) 0.275 
  D1 Na (meq/l) 143(124-157) 143(128-159) 0.707 
  D2 AST (IU/l) 307(21-8288) 299(33-7117) 0.491 
  D2 INR 1.20(0.50-6.9) 1.17(0.80-4.80) 0.370 
  D2 Lactate (mmol/l) 1.2(0.4-20) 1.20(0.3-10) 0.500 
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  D2 Na (meq/l) 140(124-163) 141(95-157) 0.217 
  D3 AST (IU/l) 164(1-5635) 144(27-4223) 0.223 
  D3 Bilirubin (mg/dl) 2.7(0.1-25.0) 2.6(0.3-19.9) 0.289 
  D3 Creatinine (mg/dl) 1.2(0.5-20.9) 1.2(0.5-7.2) 0.364 
  D3 INR 1.1(0.85-4.41) 1.1(0.9-3.2) 0.189 
  D3 Lactate (mmol/l) 1.1(0.1-10.5) 1.1(0.1-7.9) 0.965 
  D3 Na (meq/l) 138(110-157) 139(115-160) 0.322 
  D4 AST (IU/l) 95(12-3408) 94(19-2963) 0.506 
  D4 Bilirubin (mg/dl) 3.4(0.1-37.2) 3.2(0.2-23.6) 0.346 
  D4 Creatinine (mg/dl) 1.1(0.2-8.0) 1.2(0.5-6.5) 0.555 
  D4 INR 1.1(0.9-4.4) 1.1(0.8-3.4) 0.472 
  D4 Lactate (mmol/l) 1.2(0.1-12.7) 1.2(0.3-7.4) 0.757 
  D4 Na (meq/l) 136(122-157) 137(123-153) 0.127 
  D7 AST (IU/l) 62(9-10040) 63(12-2098) 0.889 
  D7 Bilirubin (mg/dl) 3.1(0.2-44.4) 2.8(0.2-36.3) 0.440 
  D7 Creatinine (mg/dl) 1.1(0.5-7.4) 1.1(0.5-5.0) 0.248 
  D7 INR 1.1(0.8-3.2) 1.10.8-3.0) 0.742 
  D7 Lactate (mmol/l) 1.4(0.1-25) 1.3(0.1-17) 0.220 
  D7 Na (meq/l) 136(120-154) 136(117-154) 0.016 
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Figure legends: 
Figure 1: Sequential changes in main discriminatory biochemical indices over the first week post 
liver transplantation. Median (95%CI median) values are plotted. A) Lactate B) AST C) Bilirubin D) 
Creatinine E) INR  
Figure 2: A) Derivation cohort comparison of AUROC curves. King’s PNF AUROC 0.912 (0.889 -
0.932),  USA PNF AUROC 0.776(0.774-0.806, p=0.010  compared to King’s PNF using Hanley & 
McNeil method), UK EGD AUROC 0.669 (0.634-0.704, p<0.001compared to King’s PNF using 
Hanley & McNeil method )  
B) Validation cohort comparison of AUROC curves Kings PNF AUROC 0.831 (0.789 -0.867) USA 
PNF 0.781(0.736-0.822, p=0.547 compared to King’s PNF using Hanley & McNeil method) UK 
EGD 0.674 (0.624-0.721, p=0.154 compared to King’s PNF using Hanley & McNeil method). 
Figure 3: Comparison of the performance of King’s model for diagnosis of primary non-function  
a. All patients, AUROC=0.840 (0.799-0.876), p<0.001.  
b. Excluding  patients with ALF, AUROC=0.795 (0.746-0.839), p=0.041  
c. Excluding recipients of DCD grafts, AUROC=0.854 (0.812-0.890, p<0.001 
d. Excluding recipients of partial grafts, AUROC=0.821 (0.775-0.861),p=0.003 
e. Excluding recipients of marginal grafts, AUROC=0.860 (0.814-0.898),p<0.001 
Figure 4: Pairwise comparison of AUROC for King’s model of PNF inclusive and exclusive of day-7 
variables (AUROC 0.831 v  0.818, p=0.321 for comparison using Hanley & McNeil method).  
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Figure 1: Sequential changes in main discriminatory biochemical indices over the first week post liver 
transplantation. Median (95%CI median) values are plotted. A) Lactate B) AST C) Bilirubin D) 
Creatinine E) INR  
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Figure 2: A) Derivation cohort comparison of AUROC curves. King’s PNF AUROC 0.912 (0.889 -0.932),  
USA PNF AUROC 0.776(0.774-0.806, p=0.010  compared to King’s PNF using Hanley & McNeil 
method), UK EGD AUROC 0.669 (0.634-0.704, p<0.001compared to King’s PNF using Hanley & 
McNeil method )  
B) Validation cohort comparison of AUROC curves Kings PNF AUROC 0.831 (0.789 -0.867) USA PNF 
0.781(0.736-0.822, p=0.547 compared to King’s PNF using Hanley & McNeil method) UK EGD 0.674 
(0.624-0.721, p=0.154 compared to King’s PNF using Hanley & McNeil method). 
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Figure 3: Comparison of the performance of King’s model for diagnosis of primary non-function  
a. All patients, AUROC=0.840 (0.799-0.876), p<0.001.  
b. Excluding  patients with ALF, AUROC=0.795 (0.746-0.839), p=0.041  
c. Excluding recipients of DCD grafts, AUROC=0.854 (0.812-0.890, p<0.001 
d. Excluding recipients of partial grafts, AUROC=0.821 (0.775-0.861),p=0.003 
e. Excluding recipients of marginal grafts, AUROC=0.860 (0.814-0.898),p<0.001 
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 Figure 4: Pairwise comparison of AUROC for King’s model of PNF inclusive and exclusive of day-7 
variables (AUROC 0.831 v  0.818, p=0.321 for comparison using Hanley & McNeil method).  
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SUPPLEMENTARY 
Supplementary methods for repeated measures logistic regression 
The data were transformed to fit into the data structure required of generalised estimating 
equations (GEE). The outcome variable remained the dichotomous 2-week death or re-
transplant variable and a binary logistic model used to allow for the dichotomous outcome 
variable.  
All independent variables (IVs) were included in original models with those with a trajectory 
(AST, INR, lactate, creatinine, bilirubin, use of vasopressors) marked as repeated measures. 
Factors (categorical IV) included were gender, aetiology and use of advanced cardiovascular, 
respiratory, renal support and covariates (continuous IV) were age, AST, lactate, bilirubin, 
creatinine, albumin, INR, sodium and DRI. A main effects model with a random intercept 
was chosen. 
 
Supplementary results for repeated measures logistic regression 
The final model included AST, lactate, bilirubin and pressor requirement with highly 
significant predictive accuracy and a sensitivity of 71 (55-84) % and specificity of 95 (92-97) 
%, LR+ 14 (10-20), LR- 0.3 (0.2-0.5). This was essentially the same as with the original 
proposed model with an area under the ROC curve of 0.83 as detailed below.  
 
 
Tests of Model Effects 
Source 
Type III 
Wald Chi-
Square df Sig. 
Pressors 387.207 2 .000 
AST 8.095 1 .004 
Lactate 64.079 1 .000 
Bilirubin 16.487 1 .000 
    
Dependent Variable: 2WDReTx 
Model: Pressors, AST, Lactate, Bilirubin 
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Parameter Estimates 
Parameter B Std. Error 
95% Wald Confidence Interval Hypothesis Test 
Lower Upper 
Wald Chi-
Square df Sig. 
[Pressors=0] -4.489 .2282 -4.937 -4.042 387.112 1 .000 
[Pressors=1] -3.330 .2846 -3.888 -2.773 136.983 1 .000 
AST .000 6.6782E-5 5.912E-5 .000 8.095 1 .004 
Lactate .341 .0426 .257 .424 64.079 1 .000 
Bilirubin .006 .0015 .003 .009 16.487 1 .000 
(Scale) 1       
Dependent Variable: 2WDReTx 
Model: Pressors, AST, Lactate, Bilirubin 
 
 
 
It is interesting that using a more formal approach to repeated measures without significant 
supervised variable selection led to a model with similar prognostic accuracy. The model we 
propose is a relatively simple equation and unless these more data driven techniques can 
provide much higher accuracy we do not recommend them at present. Also, they require 
data to day 7 and our model can allow stratification at day 3 where prompt preparations for 
re-transplantation can be started. We would agree that these generalised models are useful 
to explore further but suggest they could be part of a future manuscript on their use in 
these situations. However they do explicitly use bilirubin as part of their definition so they 
are incorporating the trajectory of this parameter which was not done in our simpler model.  
 
 
 
